S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
NYSE:USNA

USANA Health Sciences Competitors

$101.39
+1.25 (+1.25 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$99.08
Now: $101.39
$101.44
50-Day Range
$79.14
MA: $88.66
$100.43
52-Week Range
$43.01
Now: $101.39
$102.58
Volume151,481 shs
Average Volume112,504 shs
Market Capitalization$2.13 billion
P/E Ratio18.78
Dividend YieldN/A
Beta0.98

Competitors

USANA Health Sciences (NYSE:USNA) Vs. APHA, TLRY, CRON, ACB, SNDL, and HEXO

Should you be buying USNA stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to USANA Health Sciences, including Aphria (APHA), Tilray (TLRY), Cronos Group (CRON), Aurora Cannabis (ACB), Sundial Growers (SNDL), and HEXO (HEXO).

USANA Health Sciences (NYSE:USNA) and Aphria (NASDAQ:APHA) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.

Volatility and Risk

USANA Health Sciences has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Aphria has a beta of 2.67, indicating that its share price is 167% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for USANA Health Sciences and Aphria, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
Aphria03602.67

USANA Health Sciences presently has a consensus target price of $126.00, indicating a potential upside of 24.27%. Aphria has a consensus target price of $17.7857, indicating a potential upside of 13.21%. Given USANA Health Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe USANA Health Sciences is more favorable than Aphria.

Valuation & Earnings

This table compares USANA Health Sciences and Aphria's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion2.01$100.53 million$4.4122.99
Aphria$405.96 million12.26$-63,210,000.00($0.06)-261.83

USANA Health Sciences has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

54.1% of USANA Health Sciences shares are held by institutional investors. Comparatively, 10.3% of Aphria shares are held by institutional investors. 45.4% of USANA Health Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares USANA Health Sciences and Aphria's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.57%32.91%22.26%
Aphria-36.10%-2.30%-1.66%

Summary

USANA Health Sciences beats Aphria on 11 of the 14 factors compared between the two stocks.

USANA Health Sciences (NYSE:USNA) and Tilray (NASDAQ:TLRY) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.

Volatility and Risk

USANA Health Sciences has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Tilray has a beta of 3.12, indicating that its share price is 212% more volatile than the S&P 500.

Profitability

This table compares USANA Health Sciences and Tilray's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.57%32.91%22.26%
Tilray-242.60%-92.70%-20.70%

Insider and Institutional Ownership

54.1% of USANA Health Sciences shares are held by institutional investors. Comparatively, 12.6% of Tilray shares are held by institutional investors. 45.4% of USANA Health Sciences shares are held by insiders. Comparatively, 16.8% of Tilray shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares USANA Health Sciences and Tilray's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion2.01$100.53 million$4.4122.99
Tilray$166.98 million22.25$-321,170,000.00($1.69)-12.80

USANA Health Sciences has higher revenue and earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for USANA Health Sciences and Tilray, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
Tilray210001.83

USANA Health Sciences presently has a consensus target price of $126.00, indicating a potential upside of 24.27%. Tilray has a consensus target price of $18.3078, indicating a potential downside of 15.36%. Given USANA Health Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe USANA Health Sciences is more favorable than Tilray.

Summary

USANA Health Sciences beats Tilray on 12 of the 14 factors compared between the two stocks.

USANA Health Sciences (NYSE:USNA) and Cronos Group (NASDAQ:CRON) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Volatility and Risk

USANA Health Sciences has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500.

Profitability

This table compares USANA Health Sciences and Cronos Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.57%32.91%22.26%
Cronos Group266.31%-1.61%-1.41%

Institutional and Insider Ownership

54.1% of USANA Health Sciences shares are held by institutional investors. Comparatively, 11.8% of Cronos Group shares are held by institutional investors. 45.4% of USANA Health Sciences shares are held by insiders. Comparatively, 7.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares USANA Health Sciences and Cronos Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion2.01$100.53 million$4.4122.99
Cronos Group$25.64 million133.20$1.17 billion$0.6714.15

Cronos Group has lower revenue, but higher earnings than USANA Health Sciences. Cronos Group is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for USANA Health Sciences and Cronos Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
Cronos Group25101.88

USANA Health Sciences presently has a consensus target price of $126.00, indicating a potential upside of 24.27%. Cronos Group has a consensus target price of $8.5625, indicating a potential downside of 9.68%. Given USANA Health Sciences' stronger consensus rating and higher possible upside, analysts plainly believe USANA Health Sciences is more favorable than Cronos Group.

Summary

USANA Health Sciences beats Cronos Group on 9 of the 14 factors compared between the two stocks.

USANA Health Sciences (NYSE:USNA) and Aurora Cannabis (NYSE:ACB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Volatility and Risk

USANA Health Sciences has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 3.44, indicating that its share price is 244% more volatile than the S&P 500.

Profitability

This table compares USANA Health Sciences and Aurora Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.57%32.91%22.26%
Aurora Cannabis-1,238.94%-16.32%-13.12%

Institutional and Insider Ownership

54.1% of USANA Health Sciences shares are held by institutional investors. Comparatively, 11.9% of Aurora Cannabis shares are held by institutional investors. 45.4% of USANA Health Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares USANA Health Sciences and Aurora Cannabis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion2.01$100.53 million$4.4122.99
Aurora Cannabis$207.89 million9.12$-2,468,190,000.00($2.86)-3.36

USANA Health Sciences has higher revenue and earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for USANA Health Sciences and Aurora Cannabis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
Aurora Cannabis69001.60

USANA Health Sciences presently has a consensus target price of $126.00, indicating a potential upside of 24.27%. Aurora Cannabis has a consensus target price of $11.2445, indicating a potential upside of 17.13%. Given USANA Health Sciences' stronger consensus rating and higher possible upside, analysts plainly believe USANA Health Sciences is more favorable than Aurora Cannabis.

Summary

USANA Health Sciences beats Aurora Cannabis on 12 of the 14 factors compared between the two stocks.

USANA Health Sciences (NYSE:USNA) and Sundial Growers (NASDAQ:SNDL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Volatility and Risk

USANA Health Sciences has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 7.01, indicating that its share price is 601% more volatile than the S&P 500.

Profitability

This table compares USANA Health Sciences and Sundial Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.57%32.91%22.26%
Sundial Growers-415.89%-187.67%-72.67%

Institutional and Insider Ownership

54.1% of USANA Health Sciences shares are held by institutional investors. Comparatively, 3.3% of Sundial Growers shares are held by institutional investors. 45.4% of USANA Health Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares USANA Health Sciences and Sundial Growers' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion2.01$100.53 million$4.4122.99
Sundial Growers$75.86 million23.36$-204,570,000.00($3.17)-0.36

USANA Health Sciences has higher revenue and earnings than Sundial Growers. Sundial Growers is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for USANA Health Sciences and Sundial Growers, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
Sundial Growers12001.67

USANA Health Sciences presently has a consensus target price of $126.00, indicating a potential upside of 24.27%. Sundial Growers has a consensus target price of $1.00, indicating a potential downside of 11.89%. Given USANA Health Sciences' stronger consensus rating and higher possible upside, analysts plainly believe USANA Health Sciences is more favorable than Sundial Growers.

Summary

USANA Health Sciences beats Sundial Growers on 12 of the 14 factors compared between the two stocks.

USANA Health Sciences (NYSE:USNA) and HEXO (NYSE:HEXO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Volatility and Risk

USANA Health Sciences has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, HEXO has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Profitability

This table compares USANA Health Sciences and HEXO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.57%32.91%22.26%
HEXO-517.61%-13.15%-10.35%

Institutional and Insider Ownership

54.1% of USANA Health Sciences shares are held by institutional investors. Comparatively, 35.3% of HEXO shares are held by institutional investors. 45.4% of USANA Health Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares USANA Health Sciences and HEXO's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion2.01$100.53 million$4.4122.99
HEXO$60.46 million12.97$-406,370,000.00($0.96)-6.69

USANA Health Sciences has higher revenue and earnings than HEXO. HEXO is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for USANA Health Sciences and HEXO, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
HEXO67301.81

USANA Health Sciences presently has a consensus target price of $126.00, indicating a potential upside of 24.27%. HEXO has a consensus target price of $1.9455, indicating a potential downside of 69.70%. Given USANA Health Sciences' stronger consensus rating and higher possible upside, analysts plainly believe USANA Health Sciences is more favorable than HEXO.

Summary

USANA Health Sciences beats HEXO on 11 of the 14 factors compared between the two stocks.


USANA Health Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Aphria logo
APHA
Aphria
1.5$15.71+6.4%$4.98 billion$405.96 million-26.63Gap Down
Tilray logo
TLRY
Tilray
1.0$21.63+4.7%$3.72 billion$166.98 million-4.76Gap Down
Cronos Group logo
CRON
Cronos Group
0.6$9.48+1.7%$3.42 billion$25.64 million39.50Insider Selling
Analyst Revision
Gap Down
Aurora Cannabis logo
ACB
Aurora Cannabis
1.3$9.60+2.3%$1.89 billion$207.89 million-0.39Decrease in Short Interest
Sundial Growers logo
SNDL
Sundial Growers
1.0$1.14+1.8%$1.77 billion$75.86 million-0.44Increase in Short Interest
Gap Down
HEXO logo
HEXO
HEXO
0.9$6.42+1.6%$784.29 million$60.46 million-1.32Gap Down
ChromaDex logo
CDXC
ChromaDex
0.9$10.73+10.7%$662.99 million$46.29 million-28.24Upcoming Earnings
Gap Up
MediWound logo
MDWD
MediWound
1.4$5.02+3.4%$136.73 million$31.79 million-12.55Analyst Report
Decrease in Short Interest
Gap Down
Natural Alternatives International logo
NAII
Natural Alternatives International
0.4$14.36+0.9%$91.30 million$118.88 million179.52Increase in Short Interest
Gap Down
HAPP
Happiness Biotech Group
0.6$1.87+1.1%$48.43 million$65.06 million0.00
MTEX
Mannatech
1.1$18.60+1.4%$38.84 million$157.73 million5.72Dividend Announcement
News Coverage
Gap Up
FSD Pharma logo
HUGE
FSD Pharma
0.3$1.69+5.3%$32.38 million$190,000.00-0.38Upcoming Earnings
Gap Down
CYAN
Cyanotech
0.6$3.64+2.5%$22.19 million$31.90 million36.40News Coverage
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.